Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SGJ-705 combined with SSGJ-612 with or without chemotherapy in HER2-expressing advanced malignant solid tumors
CTR20262274Phase 2Active
- Sponsor
- 3SBio
- Start
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SSGJ-705 and SSGJ-612 in Nonhematologic neoplasms, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by 3SBio. Primary endpoints: Safety and Objective response rate. Started Aug 2026; status: active.
02
Drugs
SSGJ-705SSGJ-612
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20262274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262274.